Literature DB >> 27731953

ExplorinG frailty and mild cognitive impairmEnt in kidney tRansplantation to predict biomedicAl, psychosocial and health cost outcomeS (GERAS): protocol of a nationwide prospective cohort study.

Oliver Mauthner1, Veerle Claes1, Jeremy Walston2, Sandra Engberg1,3, Isabelle Binet4, Michael Dickenmann5, Déla Golshayan6, Karine Hadaya7, Uyen Huynh-Do8, Stefano Calciolari9, Sabina De Geest1,10.   

Abstract

AIM: To present the rationale, design and methodology of the GERAS project, which examines whether assessment of frailty and mild cognitive impairment could enhance risk prediction for biomedical, psychosocial outcomes and foster efficient resource allocation in kidney transplantation.
BACKGROUND: For the burgeoning cohort of older patients considered for kidney transplantation, evidence gaps regarding frailty and mild cognitive impairment limit clinical decision-making and medical management. As known risk factors for 'hard' clinical outcomes in chronic illness, both require further study in transplantation. Integrating these and other bio-psychosocial factors into a comprehensive pre-transplant patient assessment will provide insights regarding economic implications and may improve risk prediction.
DESIGN: A nation-wide multi-centre prospective cohort study nested in the Swiss Transplant Cohort Study.
METHODS: Our nationally representative convenience sample includes 250 adult kidney transplant recipients. Data sources include the Swiss Transplant Cohort Study and primary data collected at time of transplantation, 6 months, 1 and 2 years post-transplant via established measures (the Montreal Cognitive Assessment, Psychosocial Questionnaire, Fried Frailty Instrument and a blood analysis), investigator-developed instruments and datasets compiled by hospitals' management control units, sickness funds, the Swiss Federal Statistical Office and the European Renal Association. Descriptive, competing risk survival and mixed effects analyses will be performed. Research Ethics Committee approval was obtained in January 2016. DISCUSSION: This pioneering project jointly examines frailty and mild cognitive impairment from bio-psychosocial and health economic perspectives. Results may significantly inform risk prediction, care tailoring and resource optimization to improve health outcomes in the ageing kidney transplant cohort.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  frailty; health economics; kidney transplantation; midwives; mild cognitive impairment; nurses; nursing; older patients; risk prediction, multi-centre prospective cohort study

Mesh:

Year:  2016        PMID: 27731953     DOI: 10.1111/jan.13179

Source DB:  PubMed          Journal:  J Adv Nurs        ISSN: 0309-2402            Impact factor:   3.187


  3 in total

Review 1.  An overview of frailty in kidney transplantation: measurement, management and future considerations.

Authors:  Meera N Harhay; Maya K Rao; Kenneth J Woodside; Kirsten L Johansen; Krista L Lentine; Stefan G Tullius; Ronald F Parsons; Tarek Alhamad; Joseph Berger; XingXing S Cheng; Jaqueline Lappin; Raymond Lynch; Sandesh Parajuli; Jane C Tan; Dorry L Segev; Bruce Kaplan; Jon Kobashigawa; Darshana M Dadhania; Mara A McAdams-DeMarco
Journal:  Nephrol Dial Transplant       Date:  2020-07-01       Impact factor: 5.992

2.  Cohort profile: The Swiss Transplant Cohort Study (STCS): A nationwide longitudinal cohort study of all solid organ recipients in Switzerland.

Authors:  Susanne Stampf; Nicolas J Mueller; Christian van Delden; Manuel Pascual; Oriol Manuel; Vanessa Banz; Isabelle Binet; Sabina De Geest; Pierre-Yves Bochud; Alexander Leichtle; Stefan Schaub; Jürg Steiger; Michael Koller
Journal:  BMJ Open       Date:  2021-12-15       Impact factor: 2.692

3.  Jidong cognitive impairment cohort study: objectives, design, and baseline screening.

Authors:  Dai-Yu Song; Xian-Wei Wang; Sa Wang; Si-Qi Ge; Guo-Yong Ding; Xue-Yu Chen; Yan-Ru Chen; Hua-Min Liu; Xiao-Mei Xie; Wei-Jia Xing; Dong Li; Yong Zhou
Journal:  Neural Regen Res       Date:  2020-06       Impact factor: 5.135

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.